A 55-year-old man, nonsmoker, with a HIV-positive history came to our attention in February 2017. He was on treatment with Stribild TM , 1 capsule daily (150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 245 mg tenofovir disoproxil). The CD4+/CD8+ cellular count was 326/µL (normal values: 404-1,612); the CD3+/CD8+ cellular count was 819/µL (normal values: 220-1,219). The CD4/CD8 ratio was 0.40 (normal value: >1). Several typical genital wart lesions were present at the penis shaft and at the level of the neck and the corona of glans. These lesions were present for 2 years. Several cryotherapy sessions (a total of 10 procedures) had been performed with partial success. At the initial visit a total of 5 lesions were present. Treatment with topical Polyphenon E 10% 3 times a day was prescribed and started. After 1 month of treatment the lesions were reduced to 2. Treatment was very well tolerated. After 8 weeks of treatment no more lesions were observed and therefore a complete clearance was obtained. Local tolerability was evaluated to be very good by the patient.
Introduction
Genital warts (GW; condylomata acuminata) are a very common and contagious sexually transmitted disease caused by skin infection with human papillomavirus (HPV) [1] . HPV has a specific tropism for squamous stratified epithelium [2] . This infection is in general acquired through direct genital contact. Minor trauma facilitates the penetration of the virus. Penile shaft, glans, vulvar and perianal regions are commonly affected [3] . HPV infection is characterized by a relevant immune evasion mechanism that inhibits and delays the host immune response to the virus [4] . Genotypes 6 and 11 are the most common HPV involved in GW formation [5] . GW lesions manifest as variable in size and shape. Lesions could be soft papules or plaques on anogenital skin. Cryotherapy, podophyllotoxin, imiquimod, and laser therapy are commonly used in GW [6] . However, available treatments are in general still unsatisfactory due to low efficacy and clearance rate, low local tolerability, and high recurrence rate [7] . Topical Polyphenon E 10% has been recently evaluated in immunocompetent subjects with multiple GW [8] . Polyphenon E, applied 3 times a day for up to 16 weeks, induced a complete clearance rate in more than 50% of patients [9] . In addition, the recurrence rate at 3 months after the conclusion of the therapy was particularly low (<6%) [9] . Polyphenon E is a quantified extract of green tea leaves (Camellia sinensis) where the main active substance is epigallocatechin gallate (EGCG), a polyphenol substance which represents the major component of the catechin fraction [10] . EGCG has potent antioxidant, antiinflammatory and proapoptotic actions, which could explain its antiviral properties [11] . Recent data have shown that EGCG is able to modulate the cellular genes involved in Tolllike receptor production and in the mechanisms of apoptosis [12] . The product has shown a general good safety profile. Local skin reactions like erythema and edema, in general mild to moderate, were reported in most treated subjects [13] . No data are available regarding the efficacy and the tolerability of Polyphenon E in immunocompromised subjects. We report the clinical efficacy and the tolerability of Polyphenon E 10% ointment (Veregen TM ; Medigene, Germany) in an HIV-positive subject with multiple "difficult-to-treat" GW.
Case Description
A 55-year-old man, nonsmoker, with a HIV-positive history came to our attention in February 2017. He was on treatment with Stribild TM , 1 capsule daily (150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 245 mg tenofovir disoproxil). The CD4+/CD8+ cellular count was 326/µL (normal values: 404-1,612); the CD3+/CD8+ cellular count was 819/µL (normal values: 220-1,219). The CD4/CD8 ratio was 0.40 (normal value: >1). Several typical GW lesions were present at the penis shaft and at the level of the neck and the corona of glans (Fig. 1) . These lesions were present for 2 years. Several cryotherapy sessions (a total of 10 procedures) had been performed with partial success. At the initial visit a total number of 5 lesions were present (Fig. 1) . Treatment with topical Polyphenon E 10% 3 times a day was prescribed and started. After 1 month of treatment the lesions were reduced to 2. Treatment was very well tolerated. After 8 weeks of treatment no more lesions were observed and therefore a complete clearance was obtained (Fig. 2) . Local tolerability was evaluated to be very good by the patient.
Discussion
Polyphenon E ointment is considered an effective, well-tolerated, self-applicable topical treatment of GW in immunocompetent subjects [14] . Clinical efficacy and tolerability was evaluated in randomized vehicle-controlled phase III trials in more than 1,000 patients [15] . A complete clearance rate was observed in 51% of the treated subjects. The mean treatment duration for complete clearance was between 14 and 16 weeks [16] . GW are very common in immunocompromised subjects [17] . HIV infection appears to alter the natural history of HPV-associated lesions and oncogenesis [18] , and HIV-positive patients have a substantial high risk of suffering from GW in comparison with HIV-negative immunocompetent subjects. HIV-positive patients often develop multiple papillomatous lesions in the genital area and also in the extragenital area such as the oral cavity [19] . Goldstone et al. [20] have demonstrated that in HIV subjects the prevalence of any tested HPV type was 18.5% in the penis, 17.1% in the scrotum, 33.0% in the perineal/perianal region, 42.4% in the anal canal, and 48.0% at any site. Antiretroviral therapy is not able to prevent the development of HPVassociated lesions and does not eliminate HPV infection [21] . The treatment of GW in immunocompromised subjects can be particularly disappointing. Data regarding the efficacy of Polyphenon E in immunocompromised subjects are so far lacking. EGCG has an antiviral action through pathways triggering cell growth arrest and increasing proapoptotic molecules like p53 and p16 [22] . EGCG is able to interfere with the cellular activity of E6 and E7, 2 HPV virus proteins [23] . E6 and E7 are involved in the process of apoptosis inhibition and in the mechanisms of immune evasion [24] . Therefore, Polyphenon E could express anti-HPV action through multiple mechanisms. The gene modulation expressed by EGCG could be of help in fighting HPV lesions in HIV patients. In this case report, we have shown a high clinical efficacy of Polyphenon E in the treatment of multiple "difficult-to-treat" GW in an HIVpositive subject. It is remarkably that complete clearance of GW lesions was achieved in only 8 weeks of treatment, which is a shorter treatment period in comparison with the mean duration of treatment for GW clearance in immunocompetent patients. This case report suggests that topical Polyphenon E 10% could be an effective therapeutic strategy in subjects with GW and immunosuppression. Specific controlled trials in this specific population are warranted.
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